Key Highlights
- EUROAPI (LSE:0EAP) fell 27.11% to €0.922 on July 30, 2026; the London line is quoted in euros, not pence
- The trigger was first-half 2026 results published July 29: net sales of €356.5 million, down about 13.5%, and a net loss widening to €141.5 million from €28.5 million a year earlier
- The results confirmed an agreement to divest the troubled Brindisi site in Italy as part of the FOCUS-27 restructuring
- Full-year 2025 showed improving earnings quality - a 7.8% core EBITDA margin and net cash of €68.2 million - but management guides to a further roughly 10% comparable sales decline in 2026
- No single line item was verified as explaining the exact 27% move, but the wider loss and continued revenue contraction are the evidence-based drivers
A Bruising Session for a Company Mid-Turnaround
Shares in EUROAPI (LSE:0EAP), the French maker of active pharmaceutical ingredients spun out of Sanofi, tumbled on Thursday, July 30, 2026, extending a bruising run for a company still deep in a multi-year turnaround. By early afternoon in London the stock was quoted at €0.922, down 27.11% on the day. The slide followed the group's first-half 2026 results, published the previous afternoon on July 29. The company itself struck an upbeat note, saying the figures "confirm commercial and operational resilience" and that its transformation was "progressing as planned". The market disagreed, and the fall left the business valued at under €100 million.
What Happened to the Shares
The London line 0EAP is an international order-book quotation of EUROAPI SA, whose primary listing is on Euronext Paris; crucially, it is priced in euros, not pence, so the €0.922 quote and the roughly €93 million market capitalization both reflect the company's home currency. The move was a price fall rather than a total-return figure, and EUROAPI pays no dividend to cushion it. The timing points to the first-half results as the trigger: the numbers landed after the Paris market closed on July 29, and thin trading in a small-cap amplified the single-session reaction.
Understanding the Business
EUROAPI was carved out of Sanofi and floated in 2022 as one of the largest dedicated producers of active pharmaceutical ingredients, or APIs. It makes roughly 200 of them, supplying its former parent and other drugmakers across more than 80 countries. After recent disposals its manufacturing footprint is concentrated in France, Germany and Hungary, with the Italian site at Brindisi now earmarked for divestment. Sanofi remains both the largest customer and, alongside the French state-backed investor Bpifrance, a major shareholder. The story rests on two ideas: that Europe wants more of its medicine supply chain onshore, and that EUROAPI can shift towards higher-value, differentiated products while shrinking a legacy cost base under its restructuring programme, branded FOCUS-27.
The Latest Financial and Operational Developments
The first-half 2026 results were the immediate catalyst. Net sales fell to €356.5 million from €412.1 million a year earlier, a decline of roughly 13.5%, while the net loss widened sharply to €141.5 million from €28.5 million a year before. The company also confirmed an agreement to divest the Brindisi site, whose production problems had dogged it since a quality suspension in 2024. Full-year 2025 results, published on March 3, 2026, had shown net sales of €848.2 million, down 7.0%, and a net loss of €211.2 million, though core EBITDA rose to €66.2 million - a 7.8% margin, up from 5.5% - with net cash of €68.2 million at year-end. Guidance was more sobering: for 2026 management pointed to net sales falling around 10% on a comparable basis, citing portfolio rationalization and reduced Sanofi demand, with the core EBITDA margin broadly in line with 2025, and acknowledged that the €75-80 million incremental core EBITDA target once pencilled in for 2027 would not be met.
What May Be Driving the Sell-Off
The proximate cause is not in serious doubt: investors reacted to the first-half results. Two features stand out. The first is the top line: a further 13.5% fall in net sales confirmed that revenue is still contracting, consistent with guidance for a roughly 10% comparable decline across 2026, undercutting the recovery narrative. The second, and arguably more alarming, is the scale of the loss: a €141.5 million net loss for a single half is far larger than the sales fall alone would imply, which suggests sizeable non-cash charges, most plausibly impairments and costs tied to the Brindisi disposal. The full breakdown could not be independently verified here. No single confirmed line item explains the exact magnitude of the 27% move, but the direction of travel in the results is a sufficient, evidence-based explanation.
The Foundations of a Genuine Turnaround
For all the gloom, the turnaround has foundations. Core EBITDA margin climbed to 7.8% in 2025 from 5.5% the year before, and the FOCUS-27 programme has delivered around €20 million of operating-cost savings. Cash is a second positive: the group generated €51.5 million of free cash flow in 2025 and ended the year with net cash of €68.2 million, a buffer many loss-making small-caps lack. Strategically, exiting Brindisi removes a persistent source of quality issues and losses, letting management concentrate on a leaner base of sites and on higher-margin, differentiated products. The longer-term backdrop - European governments' desire to reshore critical medicine supply chains - is a potential source of demand, and the anchor stakes held by Sanofi and Bpifrance, locked up to December 2026, offer some stability.
The Risks Weighing on the Story
The risks are clear and currently dominant. Sales are still falling, and 2026 guidance implies another year of contraction. Heavy net losses - €211.2 million in 2025 and €141.5 million in the first half of 2026 - cannot continue indefinitely without eroding the cash cushion or forcing a dilutive capital raise. Customer concentration is a structural vulnerability: reduced Sanofi demand was explicitly cited as a drag on 2026 sales. Execution risk on the disposals is real, too, as site divestments in this industry can involve cash contributions to the buyer rather than proceeds. Management has also conceded that its 2027 core EBITDA uplift target will not be achieved, and this remains a small, euro-denominated stock on London's international order book, where liquidity is thin and price swings can be violent.
What to Watch Next
Several markers will show whether Thursday's reaction was an overshoot or a fair reassessment. The most important is the second-half sales trajectory against guidance for a roughly 10% comparable decline, and whether the core EBITDA margin holds broadly in line with 2025. Investors will also want the terms of the Brindisi divestment - including whether the exit involves a cash cost - and clarity on what drove the enlarged first-half loss; the net cash position will show how much runway remains. The December 2026 expiry of the Sanofi and Bpifrance lock-up is another date to note, as is any update ahead of the full-year 2026 results, expected in early 2027.
Conclusion
EUROAPI (LSE:0EAP) has been reset sharply lower after first-half results that paired a further drop in sales with a much wider loss. The company can point to genuine progress on margins, cost savings and cash generation, and its role in Europe's push for medicine-supply resilience gives it a credible long-term rationale. Yet the top line is still shrinking, the losses remain large, and management has already walked back a key medium-term profit target. Thursday's 27% fall reflects a market weighting the risks over the recovery; whether that proves too harsh will depend on the pace of the FOCUS-27 turnaround and the terms on which EUROAPI exits Brindisi.






Please wait processing your request...